Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - ...

DURHAM, N.C. – The progression of the artery-clogging disease atherosclerosis is linked to the inability of specialized bone marrow cells to continuously repair damage to the arterial lining, Duke ...

When a traumatic injury occurs to an artery, if a patient’s own veins aren't available for use as a bypass graft, they’ll typically have to be treated either with a synthetic implant or with surgical ...

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

For applications beyond extremity vascular trauma, Symvess remains investigational and has not received regulatory approval. In other recent news, Humacyte has announced plans to file a Marketing ...

A new research paper was published in Aging, titled "Reduction of double-strand DNA break repair exacerbates vascular aging." Advanced age is the greatest risk factor for cardiovascular disease (CVD), ...